Effect of GLP-1 receptor agonist on digestive tract movement evaluation using capsule endoscopy

Effect of GLP-1 receptor agonist on digestive tract movement evaluation using capsule endoscopy - Effect of GLP-1 receptor agonist on digestive tract movement evaluation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021686

Enrollment

Registered

2016-03-30

Start date

2015-02-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 DM

Interventions

liraglutide group, administration of the drug by titration at 0.3 mg at 7:30 a.m. (before breakfast) was started, and the dose was increased by 0.3 mg every week until it reached 0.9 mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient with type 2 DM doing a hospitalizing for diabetes Patients with no history of treatment to GLP-1 or DDP-4 inhibitor

Exclusion criteria

Exclusion criteria: Type 1 DM Severe diabetic neuropathy history of pancreatitis Pregnancy

Design outcomes

Primary

Measure	Time frame
Capsule endoscopy was performed once administration of the liraglutide at 0.9 mg for 1 week or more.	—

Countries

Japan

Contacts

Public ContactNakatani Yuki

Dokkyo Medical University Nikko Medical Center Diabetes and Endcrinology

yu-naka@dokkyomed.ac.jp0288-76-1515

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026